Latest news

• BMS' Opdivo backed as melanoma therapy in EU

  FDA approval as a second-line non-small cell lung cancer (NSCLC) therapy - a much larger market opportunity - in March. ... Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally

• Running medical meetings

  The sensitivities of the 'world' sector manifest in secretive meetings, 24-hour emails, decisions and non-decisions, last minute changes and demands, security focus, approvals… and the list goes on.

• FDA approves sleep disorder drug for blind people

  Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called non-24-hour sleep-wake disorder, which causes problems in the sleep cycle of blind ... Non-24 affects people who are completely blind as light does

• FDA panel backs sleep pattern drug for blind

  A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... As a result, they can "fully enjoy the opportunities

• FDA sets new date for Eliquis review in atrial fibrillation

  The filing draws on data from the ARISTOTLE and AVERROES studies, which together enrolled 24, 000 patients with non-valvular AF and found that the new drug was more effective than ... Other anticoagulants currently available in the US for the prevention